“Selective Serotonin Reuptake Inhibitors Response and the Impact of CYP2C19 Metabolizer Status”, Precis. Med. Com., vol. 2, no. 1, pp. 05–07, Jun. 2022, doi: 10.55627/pmc.002.01.0097.